Headlines about MannKind (NASDAQ:MNKD) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.9681238075744 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

A number of research firms have weighed in on MNKD. Zacks Investment Research upgraded MannKind from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. HC Wainwright started coverage on MannKind in a research report on Tuesday, October 10th. They set a “buy” rating on the stock. ValuEngine downgraded MannKind from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Maxim Group reissued a “hold” rating on shares of MannKind in a research report on Wednesday, November 1st. Finally, BidaskClub downgraded MannKind from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Five research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the stock. MannKind presently has an average rating of “Sell” and a consensus target price of $0.92.

MannKind (NASDAQ MNKD) opened at $2.66 on Wednesday. MannKind has a 12-month low of $0.67 and a 12-month high of $6.96. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31. The stock has a market capitalization of $275.78, a price-to-earnings ratio of -9.85 and a beta of 3.08.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.11). MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. The firm had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. During the same period in the previous year, the company posted $1.30 EPS. MannKind’s quarterly revenue was down 98.7% compared to the same quarter last year. research analysts forecast that MannKind will post -1.13 earnings per share for the current fiscal year.

In related news, Director Kent Kresa acquired 166,600 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The shares were bought at an average price of $6.00 per share, with a total value of $999,600.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Stuart A. Tross acquired 39,840 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were bought at an average cost of $2.52 per share, for a total transaction of $100,396.80. Following the transaction, the vice president now owns 59,840 shares of the company’s stock, valued at $150,796.80. The disclosure for this purchase can be found here. Insiders have bought a total of 214,440 shares of company stock worth $1,118,317 in the last three months. Corporate insiders own 1.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/01/03/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-mannkind-mnkd-share-price.html.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.